Table Of Contents:
1 Introduction	7
1.1 Industry Definition and Research Scope	7
1.1.1 Industry Definition	7
1.1.2 Research Scope	8
1.2 Research Methodology	11
1.2.1 Overview of Market Research Methodology	11
1.2.2 Market Assumption	12
1.2.3 Secondary Data	12
1.2.4 Primary Data	12
1.2.5 Data Filtration and Model Design	13
1.2.6 Market Size/Share Estimation	14
1.2.7 Research Limitations	15
1.3 Executive Summary	16
2 Market Overview and Dynamics	18
2.1 Market Size and Forecast	18
2.1.1 Impact of COVID-19 on World Economy	21
2.1.2 Impact of COVID-19 on the Market	24
2.2 Major Growth Drivers	26
2.3 Market Restraints and Challenges	31
2.4 Emerging Opportunities and Market Trends	34
2.5 Porter’s Fiver Forces Analysis	38
3 Segmentation of North America Market by Product Type	42
3.1 Market Overview by Product Type	42
3.2 Recombinant Non-glycosylated Biosimilars	44
3.2.1 Insulin	46
3.2.2 Recombinant Human Growth Hormone (rHGH)	47
3.2.3 Granulocyte Colony Stimulating Factor	48
3.2.4 Interferon	49
3.3 Recombinant Glycosylated Biosimilars	50
3.3.1 Monoclonal Antibodies (mAb)	51
3.3.2 Erythropoietin (EPO)	52
3.3.3 Follicle Stimulating Hormone	53
3.4 Recombinant Peptides and Others	54
3.4.1 Tumor Necrosis Factor (TNF)-Inhibitor	55
3.4.2 Parathyroid Hormone	56
3.4.3 Enzymes, Immunomodulators, GnRH Analogs and Others	57
4 Segmentation of North America Market by Indication	58
4.1 Market Overview by Indication	58
4.2 Cancer	60
4.3 Autoimmune Disease	61
4.4 Blood Disorder	62
4.5 Diabetes	63
4.6 Growth Hormone Deficiency	64
4.7 Infectious Diseases	65
4.8 Other Indications	66
5 Segmentation of North America Market by Manufacturing	67
5.1 Market Overview by Manufacturing	67
5.2 Contract Manufacturing	69
5.3 Inhouse Manufacturing	70
6 Segmentation of North America Market by End User	71
6.1 Market Overview by End User	71
6.2 Hospitals and Clinics	73
6.3 Research Institutes	74
6.4 Other End Users	75
7 North America Market 2019-2030 by Country	76
7.1 Overview of North America Market	76
7.2 U.S.	79
7.3 Canada	89
7.4 Mexico	91
8 Competitive Landscape	93
8.1 Overview of Key Vendors	93
8.2 New Product Launch, Partnership, Investment, and M&A	97
8.3 Company Profiles	98
AMEGA Biotech S.A.	98
Apotex Inc.	100
Biocon Ltd	101
Biogen Inc.	102
Boehringer Ingelheim	103
Celltrion, Inc.	104
Dr. Reddy’s Laboratories Ltd.	105
Eli Lilly and Company	106
Intas Pharmaceuticals Ltd.	107
LG Chem, Ltd.	108
Merck and Co. Inc.	109
Mylan N.V.	110
Pfizer Inc.	111
Samsung Biologics Co., Ltd.	112
Sandoz International GmbH	113
STADA Arzneimittel AG	114
Teva Pharmaceutical Industries Ltd.	115
RELATED REPORTS	116

List Of Tables:

Table 1.  Snapshot of North America Biosimilars Market in Balanced Perspective, 2019-2030	17
Table 2. Growth Rate of World GDP, 2020-2022	22
Table 3. World Health Spending by Region, $ bn, 2013-2020	30
Table 4.  Main Product Trends and Market Opportunities in North America Biosimilars Market	34
Table 5. North America Biosimilars Market by Product Type, 2019-2030, $ mn	42
Table 6. North America Biosimilars Market: Recombinant Non-glycosylated Biosimilars by Product, 2019-2030, $ mn	45
Table 7. North America Biosimilars Market: Recombinant Glycosylated Biosimilars by Product, 2019-2030, $ mn	50
Table 8. North America Biosimilars Market: Recombinant Peptides and Others by Product, 2019-2030, $ mn	54
Table 9. North America Biosimilars Market by Indication, 2019-2030, $ mn	58
Table 10. North America Biosimilars Market by Manufacturing, 2019-2030, $ mn	67
Table 11. North America Biosimilars Market by End User, 2019-2030, $ mn	71
Table 12. North America Biosimilars Market by Country, 2019-2030, $ mn	77
Table 13. U.S. Biosimilars Market by Product Type, 2019-2030, $ mn	82
Table 14. U.S. Biosimilars Market by Indication, 2019-2030, $ mn	82
Table 15. U.S. Biosimilars Market by End User, 2019-2030, $ mn	82
Table 16. FDA Approved Biosimilars in U.S., 2015-2020	83
Table 17. U.S. Select Pending Biosimilar BLAs as of December 2020	87
Table 18. U.S. Biosimilar Market Share (market share data through July 2020)	88
Table 19. Canada Biosimilars Market by Product Type, 2019-2030, $ mn	90
Table 20. Canada Biosimilars Market by Indication, 2019-2030, $ mn	90
Table 21. Canada Biosimilars Market by End User, 2019-2030, $ mn	90
Table 22. Mexico Biosimilars Market by Product Type, 2019-2030, $ mn	92
Table 23. Mexico Biosimilars Market by Indication, 2019-2030, $ mn	92
Table 24. Mexico Biosimilars Market by End User, 2019-2030, $ mn	92
Table 25. Breakdown of World Market by Key Vendor, 2020, %	95
Table 26. AMEGA Biotech S.A.: Company Snapshot	98
Table 27. AMEGA Biotech S.A.: Business Segmentation	98
Table 28. AMEGA Biotech S.A.: Product Portfolio	99
Table 29. AMEGA Biotech S.A.: Revenue, 2018-2020, $ mn	99

List Of Figures:

Figure 1. Research Method Flow Chart	11
Figure 2. Bottom-up Approach and Top-down Approach for Market Estimation	14
Figure 3. North America Market Forecast in Optimistic, Conservative and Balanced Perspectives, 2019-2030	16
Figure 4. North America Biosimilars Market, 2019-2030, $ mn	18
Figure 5. EMA and FDA Biosimilar Approvals, 2015 - 2019	19
Figure 6. EMA-approved Biosimilars Distribution by Reference Product and Therapeutic Area	19
Figure 7. FDA-approved Biosimilars Distribution by Reference Product and Therapeutic Area	20
Figure 8. Impact of COVID-19 on Business	24
Figure 9. Primary Drivers and Impact Factors of North America Biosimilars Market	26
Figure 10.  Worldwide Geriatric Population (60 years and above) by Regions, 2015 & 2030, million	29
Figure 11. World Population 65 and Over, % of Total Population, 1950-2060	29
Figure 12. Primary Restraints and Impact Factors of North America Biosimilars Market	31
Figure 13. Investment Opportunity Analysis	35
Figure 14. Porter’s Fiver Forces Analysis of North America Biosimilars Market	38
Figure 15. Breakdown of North America Biosimilars Market by Product Type, 2019-2030, % of Revenue	43
Figure 16. North America Addressable Market Cap in 2021-2030 by Product Type, Value ($ mn) and Share (%)	43
Figure 17. North America Biosimilars Market by Product Type: Recombinant Non-glycosylated Biosimilars, 2019-2030, $ mn	44
Figure 18. North America Biosimilars Market by Recombinant Non-glycosylated Biosimilars: Insulin, 2019-2030, $ mn	46
Figure 19. North America Biosimilars Market by Recombinant Non-glycosylated Biosimilars: Recombinant Human Growth Hormone (rHGH), 2019-2030, $ mn	47
Figure 20. North America Biosimilars Market by Recombinant Non-glycosylated Biosimilars: Granulocyte Colony Stimulating Factor, 2019-2030, $ mn	48
Figure 21. North America Biosimilars Market by Recombinant Non-glycosylated Biosimilars: Interferon, 2019-2030, $ mn	49
Figure 22. North America Biosimilars Market by Product Type: Recombinant Glycosylated Biosimilars, 2019-2030, $ mn	50
Figure 23. North America Biosimilars Market by Recombinant Glycosylated Biosimilars: Monoclonal Antibodies (mAb), 2019-2030, $ mn	51
Figure 24. North America Biosimilars Market by Recombinant Glycosylated Biosimilars: Erythropoietin (EPO), 2019-2030, $ mn	52
Figure 25. North America Biosimilars Market by Recombinant Glycosylated Biosimilars: Follicle Stimulating Hormone, 2019-2030, $ mn	53
Figure 26. North America Biosimilars Market by Product Type: Recombinant Peptides and Others, 2019-2030, $ mn	54
Figure 27. North America Biosimilars Market by Recombinant Peptides and Others: Tumor Necrosis Factor (TNF)-Inhibitor, 2019-2030, $ mn	55
Figure 28. North America Biosimilars Market by Recombinant Peptides and Others: Parathyroid Hormone, 2019-2030, $ mn	56
Figure 29. North America Biosimilars Market by Recombinant Peptides and Others: Enzymes, Immunomodulators, GnRH Analogs and Others, 2019-2030, $ mn	57
Figure 30. Breakdown of North America Biosimilars Market by Indication, 2019-2030, % of Sales Revenue	59
Figure 31. North America Addressable Market Cap in 2021-2030 by Indication, Value ($ mn) and Share (%)	59
Figure 32. North America Biosimilars Market by Indication: Cancer, 2019-2030, $ mn	60
Figure 33. North America Biosimilars Market by Indication: Autoimmune Disease, 2019-2030, $ mn	61
Figure 34. North America Biosimilars Market by Indication: Blood Disorder, 2019-2030, $ mn	62
Figure 35. North America Biosimilars Market by Indication: Diabetes, 2019-2030, $ mn	63
Figure 36. North America Biosimilars Market by Indication: Growth Hormone Deficiency, 2019-2030, $ mn	64
Figure 37. North America Biosimilars Market by Indication: Infectious Diseases, 2019-2030, $ mn	65
Figure 38. North America Biosimilars Market by Indication: Other Indications, 2019-2030, $ mn	66
Figure 39. Breakdown of North America Biosimilars Market by Manufacturing, 2019-2030, % of Sales Revenue	68
Figure 40. North America Addressable Market Cap in 2021-2030 by Manufacturing, Value ($ mn) and Share (%)	68
Figure 41. North America Biosimilars Market by Manufacturing: Contract Manufacturing, 2019-2030, $ mn	69
Figure 42. North America Biosimilars Market by Manufacturing: Inhouse Manufacturing, 2019-2030, $ mn	70
Figure 43. Breakdown of North America Biosimilars Market by End User, 2019-2030, % of Revenue	72
Figure 44. North America Addressable Market Cap in 2021-2030 by End User, Value ($ mn) and Share (%)	72
Figure 45. North America Biosimilars Market by End User: Hospitals and Clinics, 2019-2030, $ mn	73
Figure 46. North America Biosimilars Market by End User: Research Institutes, 2019-2030, $ mn	74
Figure 47. North America Biosimilars Market by End User: Other End Users, 2019-2030, $ mn	75
Figure 48. Breakdown of North America Biosimilars Market by Country, 2019 and 2030, % of Revenue	77
Figure 49. Contribution to North America 2021-2030 Cumulative Market by Country, Value ($ mn) and Share (%)	78
Figure 50. U.S. Biosimilars Market, 2019-2030, $ mn	80
Figure 51. Biosimilar Approvals and Launches in U.S., 2015-2020	80
Figure 52. Canada Biosimilars Market, 2019-2030, $ mn	89
Figure 53.  Biosimilars Market in Mexico, 2019-2030, $ mn	91
Figure 54. Growth Stage of North America Biosimilars Industry over the Forecast Period	93

Key Players (this may not be a complete list and extra companies can be added upon request): 
AMEGA Biotech S.A.
Apotex Inc.
Biocon Ltd
Biogen Inc.
Boehringer Ingelheim
Celltrion, Inc.
Dr. Reddy’s Laboratories Ltd.
Eli Lilly and Company
Intas Pharmaceuticals Ltd.
LG Chem, Ltd.
Merck and Co. Inc.
Mylan N.V.
Pfizer Inc.
Samsung Biologics Co., Ltd.
Sandoz International GmbH
STADA Arzneimittel AG
Teva Pharmaceutical Industries Ltd. 
(Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)